Functional bowel symptoms in quiescent inflammatory bowel diseases: role of epithelial barrier disruption and low-grade inflammation.
about
Systematic review and meta-analysis of lactose digestion, its impact on intolerance and nutritional effects of dairy food restriction in inflammatory bowel diseasesNeuroimmunomodulation in the Gut: Focus on Inflammatory Bowel DiseasePotential Benefits of Dietary Fibre Intervention in Inflammatory Bowel DiseaseNew and emerging therapies for the treatment of irritable bowel syndrome: an update for gastroenterologistsFlavonoids in Inflammatory Bowel Disease: A ReviewIrritable bowel syndrome: new insights into symptom mechanisms and advances in treatmentOverlapping irritable bowel syndrome and inflammatory bowel disease: less to this than meets the eye?Diagnosis and management of functional symptoms in inflammatory bowel disease in remissionHost-microbiome interaction in Crohn's disease: A familiar or familial issue?Irritable bowel syndrome and inflammatory bowel disease overlap syndrome: pieces of the puzzle are falling into placeCrosstalk between Inflammation and ROCK/MLCK Signaling Pathways in Gastrointestinal Disorders with Intestinal HyperpermeabilityIntestinal Permeability in Inflammatory Bowel Disease: Pathogenesis, Clinical Evaluation, and Therapy of Leaky GutIBS-like symptoms in patients with ulcerative colitisThe analysis of factors associated with progression of isolated terminal ileal lesionsEffects in the use of a genetically engineered strain of Lactococcus lactis delivering in situ IL-10 as a therapy to treat low-grade colon inflammation.Endoscopy-Guided Evaluation of Duodenal Mucosal Permeability in Functional Dyspepsia.Berberine alleviates dextran sodium sulfate-induced colitis by improving intestinal barrier function and reducing inflammation and oxidative stress.Control of lupus nephritis by changes of gut microbiota.Microbiota-host interactions in irritable bowel syndrome: epithelial barrier, immune regulation and brain-gut interactionsElevated circulating miR-150 and miR-342-3p in patients with irritable bowel syndrome.Intestinal inflammation and mucosal barrier function.The role of mast cells in functional GI disorders.Gastrointestinal mucosal barrier function and diseases.A gut microbial metabolite of linoleic acid, 10-hydroxy-cis-12-octadecenoic acid, ameliorates intestinal epithelial barrier impairment partially via GPR40-MEK-ERK pathway.Colitis-induced neuroplasticity disrupts motility in the inflamed and post-inflamed colon.ZAP-70 genotype disrupts the relationship between microbiota and host, leading to spondyloarthritis and ileitis in SKG mice.Cyclosporine A regulates pro-inflammatory cytokine production in ulcerative colitis.Faecalibacterium prausnitzii prevents physiological damages in a chronic low-grade inflammation murine model.Increased serum levels of lipopolysaccharide and antiflagellin antibodies in patients with diarrhea-predominant irritable bowel syndrome.Basal Plasma Levels of Copeptin are Elevated in Inactive Inflammatory Bowel Disease after Bowel Resection.IBS and IBD - separate entities or on a spectrum?The human intestinal microbiota of constipated-predominant irritable bowel syndrome patients exhibits anti-inflammatory properties.The effects of Lactobacillus plantarum on small intestinal barrier function and mucosal gene transcription; a randomized double-blind placebo controlled trial.Irritable bowel syndrome: emerging paradigm in pathophysiology.Does calprotectin level identify a subgroup among patients suffering from irritable bowel syndrome? Results of a prospective study.Dietary considerations in migraine management: does a consistent diet improve migraine?Gastrointestinal motility disorders in inflammatory bowel diseases.Tight junctions and IBS--the link between epithelial permeability, low-grade inflammation, and symptom generation?Crosstalk at the mucosal border: importance of the gut microenvironment in IBS.Prevalence and Impact of Inflammatory Bowel Disease-Irritable Bowel Syndrome on Patient-reported Outcomes in CCFA Partners.
P2860
Q26740495-F3CF5D0C-17E6-4335-8FBD-946C44EFD6BAQ26741037-21BAA3A1-99F8-4B5E-8421-02123FD7DE49Q26744514-F73D94B9-AFB9-4F60-8CD1-F14067233341Q26748617-A1576BE1-B6F3-4CC0-83A9-859A22DD52FAQ26748883-FDEBF373-B784-4420-BC99-7F2AE4C69512Q26751193-2315F0BC-5A0B-4223-B217-425855E07A65Q26765219-29DB0867-B076-47A5-B063-EC8DE722E5CAQ26768264-CFBBA4E7-ED8C-4E49-ABE7-CE50F336BAF7Q26776158-D62B469C-4012-450A-BC29-9EFFE07A6A65Q28071496-A94439A1-361C-4815-A4DA-31188941F7CCQ28079482-D24A905D-9B0A-449B-B597-98185029B6C2Q28081848-701BC983-D3FE-4475-8517-075CF7FB25C7Q28088663-58F3C3E8-6153-4FFD-A342-E26AFE7C994FQ28540843-D22185BF-5581-49CF-BE60-24230C09B424Q33578069-E4D67227-35F1-4E5B-B1A7-59A43C09499CQ33635123-C7D43897-9E7C-439E-8FC0-C89E21BA6807Q33744905-7086FFAF-FEA5-4E25-A2F8-B6DFFCCCAA9BQ33893588-D4E3482B-48A4-4DDA-8BE8-788414AEF202Q33958897-48A9DC3E-1201-4217-8E10-B649E0B0C7DCQ33993894-24369125-D926-4DFE-BB3C-283CD85C5677Q34438743-772389C0-2E62-4DE9-BB41-3648750F902EQ34486007-21C94A16-E855-4A64-A7DE-A70ADAB22EB1Q34520959-608325B3-82F4-476E-AC06-162AF1A4623AQ35048916-BFF9EC75-EE92-4F44-AB98-EF3459140ECFQ35183955-79685C96-9B2A-4A6C-879E-475BF25EBA65Q35210622-0655B8A1-D8A0-47AA-A89B-9863DD2EA4D9Q35231496-EE048074-5DC5-4144-BE51-4521927FBF48Q35336737-60D2AAB1-8973-41F3-907B-CA80F99C2BC1Q35781494-BAC1D4A4-C097-4DDC-BF08-4A036A421B6FQ35850091-C624A593-2460-49B3-921F-26D20ACC254BQ36144375-C4409CAF-9F74-4EC5-8834-A77C0A3A97BEQ37508462-2BA20901-C523-4E6A-B69D-70A00B56B07BQ37550508-56720045-1D8B-41DC-A428-73B987F9628AQ37629670-57F26D95-1459-4925-997F-109A014A654AQ37698552-7EB566A7-FDFC-4B6A-A155-C79B398B1E46Q38143665-F4ECE933-8CC1-4C7B-8245-F7802E499E67Q38177780-9CD6E041-18BA-4B01-A536-26223646AAB3Q38189138-BA86C108-D360-4D5E-8A2A-3D31468D6C62Q38275041-E0498480-5B8F-4E35-BD59-DF9AE00F5C2FQ39018445-A734F6CF-272F-4ED3-A1BE-7FE2099E1A0B
P2860
Functional bowel symptoms in quiescent inflammatory bowel diseases: role of epithelial barrier disruption and low-grade inflammation.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
Functional bowel symptoms in q ...... on and low-grade inflammation.
@en
Functional bowel symptoms in q ...... on and low-grade inflammation.
@nl
type
label
Functional bowel symptoms in q ...... on and low-grade inflammation.
@en
Functional bowel symptoms in q ...... on and low-grade inflammation.
@nl
prefLabel
Functional bowel symptoms in q ...... on and low-grade inflammation.
@en
Functional bowel symptoms in q ...... on and low-grade inflammation.
@nl
P2093
P2860
P1433
P1476
Functional bowel symptoms in q ...... ion and low-grade inflammation
@en
P2093
G Frin-Mathy
H Bzioueche
M C Saint-Paul
M Vivinus-Nébot
X Hébuterne
P2860
P304
P356
10.1136/GUTJNL-2012-304066
P407
P577
2013-07-22T00:00:00Z